Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-22T18:40:40.208Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacological and non-pharmacological treatment preferences of healthcare professionals and proxies for challenging behaviors in patients with dementia

Published online by Cambridge University Press:  18 April 2017

Sarah I. Janus ,
Jeannette G. van Manen ,
Janine A. van Til ,
Sytse U. Zuidema  and
Maarten J. IJzerman
Sarah I. Janus*
Affiliation:
Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands
Jeannette G. van Manen
Affiliation:
Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands
Janine A. van Til
Affiliation:
Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands
Sytse U. Zuidema
Affiliation:
Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
Maarten J. IJzerman
Affiliation:
Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands
*
Correspondence should be addressed to: Sarah Janus, University of Twente, Health Technology and Services Research, PO Box 217, 7500 AE Enschede, the Netherlands. Phone: +31 53 489 3915. Email: [email protected].
Get access

Abstract

Background:

Prescribing antipsychotics to patients with neuropsychiatric symptoms is a matter of concern. Physicians have to make treatment decisions for patients with dementia together with proxies and/or nurses. However, it is unknown whether physicians, nurses, and proxies’ treatment preferences are aligned; hence this study.

Methods:

Sixteen treatment attributes were selected to elicit the preferences of physicians and nurses. Ten of these attributes were used for the proxies. Preferences were estimated using a case-1 Best-Worst-Scaling design; respondents are asked to select the best and worst attribute on being presented with a hypothetical patient with dementia demonstrating neuropsychiatric symptoms. The treatments offered are: antipsychotic treatment or non-pharmaceutical regimens.

Results:

The questionnaire was filled in by 41 physicians, 81 nurses, and 59 proxies. The non-pharmacological treatment option was chosen by 52% of the proxies and 71% of the physicians and nurses. The respondents who chose antipsychotics rated the aspects “fastest result” and “most effective” as important. Physicians ranked “experience with antipsychotics” as an important aspect for prescribing antipsychotics. Only the proxies rated the aspect “having a low negative effect on the patient” as important. The nurses and elderly care physicians who chose the non-pharmaceutical treatment ranked “appropriateness” and “of little burden to the patient” as important aspects.

Conclusions:

While doctors and nurses prefer non-pharmacological interventions, proxies indicated a preference for pharmacological treatment because of the immediate effect. However, physicians follow treatment guidelines and nurses and proxies rely on the physician's recommendations. We suggest physicians should be sensitive to these differences.

Keywords

dementiapsychopharmacologynursing homes
Type
Research Article
Information
International Psychogeriatrics , Volume 29 , Issue 8 , August 2017 , pp. 1377 - 1389
Copyright
Copyright © International Psychogeriatric Association 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adamsen, J., Rundle-Thiele, S., and Whitty, J. (2013). Best-Worst scaling. . .reflections on presentation, analysis, and lessons learnt from case 3 BWS experiments. Market and Social Research, 21, 9–27.Google Scholar
Ballard, C. G., Creese, B., Corbett, A. and Aarsland, D. (2011). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opinion on Drug Safety, 10, 35–43.Google Scholar
Brodaty, H. and Arasaratnam, C. (2012). Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. American Journal of Psychiatry, 169, 946–953.CrossRefGoogle ScholarPubMed
Cohen-Mansfield, J. et al. (2005). Wisdom from the front lines: clinicians’ descriptions of treating agitation in the nursing home, a pilot study. Journal of the American Medical Directors Association, 6, 257–264.Google Scholar
Cohen-Mansfield, J. and Jensen, B. (2008a). Nursing home physicians' knowledge of and attitudes toward nonpharmacological interventions for treatment of behavioral disturbances associated with dementia. Journal of the American Medical Directors Association, 9, 491–498.CrossRefGoogle ScholarPubMed
Cohen-Mansfield, J. and Jensen, B. (2008b). Physicians' perceptions of their role in treating dementia-related behavior problems in the nursing home: actual practice and the ideal. Journal of the American Medical Directors Association, 9, 552–557.Google Scholar
Cohen-Mansfield, J., Juravel-Jaffe, A., Cohen, A., Rasooly, I. and Golander, H. (2013). Physicians’ practice and familiarity with treatment for agitation associated with dementia in Israeli nursing homes. International Psychogeriatrics, 25, 236–244.Google Scholar
Corbett, A., Burns, A. and Ballard, C. (2014). Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ, 349, g6420.Google Scholar
Cornegé-Blokland, E., Kleijer, B. C., Hertogh, C. M. and van Marum, R. J. (2012). Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: a survey in Dutch nursing homes among physicians, nurses, and family caregivers. Journal of the American Medical Directors Association, 13, 80. e81–80. e86.CrossRefGoogle ScholarPubMed
Finn, A. and Louviere, J. J. (1992). Determining the appropriate response to evidence of public concern: the case of food safety. Journal of Public Policy and Marketing, 11, 12–25.CrossRefGoogle Scholar
Flynn, T. N., Louviere, J. J., Peters, T. J. and Coast, J. (2008). Estimating preferences for a dermatology consultation using best-worst scaling: comparison of various methods of analysis. BMC Medical Research Methodology, 8, 76.Google Scholar
Gustafsson, M., Karlsson, S. and Lövheim, H. (2013). Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. BMC Pharmacology and Toxicology, 14, 1.CrossRefGoogle ScholarPubMed
Jeste, D. V. et al. (2008). ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology, 33, 957–970.Google Scholar
Kleijer, B. C. et al. (2008). Risk of cerebrovascular events in elderly users of antipsychotics. Journal of Psychopharmacology, 23, 909–914.Google Scholar
Liperoti, R., Pedone, C. and Corsonello, A. (2008). Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Current Neuropharmacology, 6, 117–124.CrossRefGoogle ScholarPubMed
Louviere, J. J., Lings, I., Islam, T., Gudergan, S. and Flynn, T. (2013). An introduction to the application of (case 1) best–worst scaling in marketing research. International Journal of Research in Marketing, 30, 292–303.Google Scholar
Louviere, J., Flynn, T. and Marley, A. (2015). Best-Worst Scaling: Theory, Methods and Applications. Cambridge: Cambridge University Press.CrossRefGoogle Scholar
Lövheim, H., Sandman, P. O., Kallin, K., Karlsson, S. and Gustafson, Y. (2006). Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. International Psychogeriatrics, 18, 713–726.Google Scholar
Najafzadeh, M. et al. (2012). Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. Genetics in Medicine, 14, 520–526.CrossRefGoogle ScholarPubMed
Nygaard, H. A., Ruths, S., Straand, J. and Naik, M. (2004). Not less but different: psychotropic drug utilization trends in Norwegian nursing homes during a 12-year period. The Bergen District Nursing Home (BEDNURS) Study. Aging Clinical and Experimental Research, 16, 277–282.Google Scholar
Petriwskyj, A. et al. (2014). Family involvement in decision making for people with dementia in residential aged care: a systematic review of quantitative literature. International Journal of Evidence-based Healthcare, 12, 64–86.Google Scholar
Poulos, C. et al. (2016). A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Therapeutic Advances in Neurological Disorders, 9, 95–104.Google Scholar
Schneider, L. S., Dagerman, K. S. and Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 294, 1934–1943.Google Scholar
Schumock, G. T. et al. (2004). Factors that influence prescribing decisions. Annals of Pharmacotherapy, 38, 557–562.Google Scholar
Selbeak, G., Kirkevold, Ø. and Engedal, K. (2007). The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. International Journal of Geriatric Psychiatry, 22, 843–849.Google Scholar
Smeets, C. H. et al. (2014). Factors related to psychotropic drug prescription for neuropsychiatric symptoms in nursing home residents with dementia. Journal of the American Medical Directors Association, 15, 835–840.Google Scholar
Theodorou, M. et al. (2009). Factors influencing prescribing behaviour of physicians in Greece and cyprus: results from a questionnaire based survey. BMC Health Services Research, 9, 150.Google Scholar
Trifiro, G. and Spina, E. (2011). Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Current Drug Metabolism, 12, 611–620.Google Scholar
van der Spek, K. et al. (2013). PROPER I: frequency and appropriateness of psychotropic drugs use in nursing home patients and its associations: a study protocol. BMC Psychiatry, 13, 307.CrossRefGoogle ScholarPubMed
van de Ven, G. et al. (2013). Effects of dementia-care mapping on residents and staff of care homes: a pragmatic cluster-randomised controlled trial. PLoS ONE, 8, e67325.Google Scholar
Vereniging Specialisten Ouderengeneeskunde (2016). Verenso [Online]. Utrecht: VERENSO. Available at: http://www.verenso.nl/; last accessed: 9 February 2016.Google Scholar
Weernink, M. G. et al. (2014). A systematic review to identify the use of preference elicitation methods in healthcare decision making. Pharmaceutical Medicine, 28, 175–185.Google Scholar
Wood-Mitchell, A., James, I. A., Waterworth, A., Swann, A. and Ballard, C. (2008). Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age and Ageing, 37, 547–552.Google Scholar
Ypma-Bakker, M. et al. (2008). Richtlijn Probleemgedrag [Guideline for the Treatment of Behavioural Disturbances]. Arnhem: Roos en Roos Press.Google Scholar
Zuidema, S. U., de Jonghe, J. F., Verhey, F. R. and Koopmans, R. T. (2011). Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. International Psychogeriatrics, 23, 1632–1639.CrossRefGoogle ScholarPubMed